Journal article icon

Journal article

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience

Abstract:
Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx002.567

Authors


Expand authors...
Publisher:
Oxford University Press Publisher's website
Journal:
Journal of Crohn's and Colitis Journal website
Volume:
11
Issue:
S1
Pages:
S301-S302
Publication date:
2017-02-01
DOI:
ISSN:
1873-9946
Pubs id:
pubs:719786
URN:
uri:7f9c9703-df1b-4787-ba58-212e164a8303
UUID:
uuid:7f9c9703-df1b-4787-ba58-212e164a8303
Local pid:
pubs:719786
Paper number:
S1

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP